| Bioactivity | Tat-braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by Tat-braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of RAF kinase in MAPK signaling pathway and for the study of BRAF mutant cancers[1]. |
| Sequence | Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Gln-{X}-Thr-Arg-His-Val-Asn-Ile-Leu-Leu-Phe-Met X=-NH-CH2-CH2-O-CH2-CH2-O-CH2-C=O- |
| Shortening | GRKKRRQRRR-{X}-TRHVNILLFM X=-NH-CH2-CH2-O-CH2-CH2-O-CH2-C=O- |
| Formula | C128H227N51O30S |
| Molar Mass | 2992.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gunderwala A Y, et al. Development of allosteric BRAF peptide inhibitors targeting the dimer interface of BRAF[J]. ACS chemical biology, 2019, 14(7): 1471-1480. |